AriBio Co., Ltd.   Report issue

For profit Phase 3
Founded: Seoul Korea, Republic of (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2018
NCT03625622
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AriBio Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

ar1001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1